KAKS

Präklinische Testung CD171- undGD2-spezifischer CAR-TZelltherapie zur Behandlung des Retinoblastoms in vivo

01/01/2019 to 31/12/2019

In this project, we want to validate date, which were generated by the work group of Dr. med. Kunkele i.R. in a preliminary project (KAKS 2017 / C05f) in vivo. In this preliminary project, a specific form of adoptive T-cell therapy was evaluated as a treatment approach for retinoblastoma. Adoptive T-cell therapy means that the patient's immune system is artificially enhanced to destroy cancer cells better and more effectively.

As a next important step in the preclinical evaluation of CAR-T cell therapy, we are now planning to validate the findings obtained in vitro on the mouse model in vivo.